SpringWorks Therapeutics, Inc.

NasdaqGS SWTX

SpringWorks Therapeutics, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2024: -42.19%

SpringWorks Therapeutics, Inc. Return on Assets (ROA) is -42.19% for the Trailing 12 Months (TTM) ending September 30, 2024, a 22.27% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

SpringWorks Therapeutics, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2023 was -54.28%, a -0.06% change year over year.
SpringWorks Therapeutics, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2022 was -54.24%, a -173.14% change year over year.
SpringWorks Therapeutics, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2021 was -19.86%.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

NasdaqGS: SWTX

SpringWorks Therapeutics, Inc.

CEO	Mr. Saqib Islam J.D.
IPO Date	Sept. 13, 2019
Location	United States
Headquarters	100 Washington Boulevard
Employees	305
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

Key trends

Past 5 years